RNAC Q1 2024 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-1.7% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$13M-228.6% margin

Net Income

-$57M-973.0% margin

EPS (Diluted)

$-10.50

QoQ Revenue Growth

-29.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$325M

Total Liabilities

$442M

Stockholders' Equity

-$117M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	-1.7%
Gross Profit	$6M	-$13M	+146.0%
Operating Income	-$13M	-$18M	+27.4%
Net Income	-$57M	-$22M	-162.3%